Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Asthma I: Introduction01:28

Asthma I: Introduction

84
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
84
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

1.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common food allergen education and exposure in infants with feeding tubes: A single-center retrospective study highlighting an educational gap.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2026
Same author

Successful treatment of eosinophilic esophagitis with dupilumab in patients under 1 year of age or less than 15 kg: a retrospective chart review of 10 patients.

The journal of allergy and clinical immunology. In practice·2026
Same author

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same author

Risk Factors for Secondary Immunodeficiency in the Aged.

The journal of allergy and clinical immunology. In practice·2026
Same author

2025 Inborn errors of immunity practice parameter: Guidance from the Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI) and the Clinical Immunology Society (CIS).

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Recommended Vaccines for Immunocompetent Older Adults: A Work Group Report of the AAAAI Asthma, Allergic & Immunologic Diseases in Older Adults Committee.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes.

Clinical reviews in allergy & immunology·2026
Same journal

β-blocker Therapy in Cholinergic Urticaria, Adrenergic Urticaria and the Aquagenic Continuum Beta-Blocker Therapy in Chronic Inducible Urticaria.

Clinical reviews in allergy & immunology·2026
Same journal

Immunopathogenesis and Cytokine Pathways in Reactive Infectious Mucocutaneous Eruption (RIME) in Pediatric Population: Infectious Triggers and Molecular Insights.

Clinical reviews in allergy & immunology·2026
Same journal

Neuropsychological Factors in Vitiligo: Mechanisms and Clinical Application.

Clinical reviews in allergy & immunology·2026
Same journal

Tertiary Lymphoid Structure: A Potential Therapeutic Target Affecting Immune Response in Autoimmune Diseases.

Clinical reviews in allergy & immunology·2026
Same journal

Differentiating Acute-onset Autoimmune Hepatitis From Drug-Induced Autoimmune-like Hepatitis: A Multicenter Study and Score Development.

Clinical reviews in allergy & immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.6K

Biological Modulators in Eosinophilic Diseases.

Panida Sriaroon1, Mark Ballow2

  • 1Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of South Florida, 140 7th ave S, CRI 4008, St. Petersburg, FL, 33701, USA. psriaroo@health.usf.edu.

Clinical Reviews in Allergy & Immunology
|August 18, 2014
PubMed
Summary
This summary is machine-generated.

Eosinophils drive inflammation in atopic diseases. Biologic therapies targeting these pathways show variable improvement, with novel treatments under investigation for eosinophilic disorders.

Keywords:
AsthmaBiologicsChurg-Strauss syndromeEosinophilic diseasesEosinophilic esophagitisEosinophilic granulomatosis with polyangiitisEosinophilsHypereosinophilic syndromeMonoclonal antibodiesNasal polyposis

More Related Videos

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

5.7K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.0K

Related Experiment Videos

Last Updated: Apr 25, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.6K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

5.7K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.0K

Area of Science:

  • Immunology
  • Inflammation Biology
  • Clinical Therapeutics

Background:

  • Eosinophils are key regulators of local and systemic inflammation.
  • Elevated eosinophil counts are implicated in the pathology of atopic and inflammatory diseases.
  • Cytokines like interleukin (IL)-5, IL-4, IL-13, and GM-CSF are crucial for eosinophil regulation.

Purpose of the Study:

  • To review the clinical application of biologic agents in treating eosinophilic diseases.
  • To summarize biologic therapies investigated in clinical trials or approved for eosinophilic conditions.

Main Methods:

  • Literature review of clinical trials and approved biologic therapies.
  • Analysis of biologic modulators targeting eosinophilic inflammatory pathways.

Main Results:

  • Biologic modulators have altered the treatment landscape for eosinophilic diseases.
  • Clinical improvement with existing biologic agents has been variable.
  • Ongoing research focuses on novel, safe, and effective targeted therapies.

Conclusions:

  • Biologic therapies offer a targeted approach to eosinophilic inflammation.
  • Further investigation into novel agents is necessary for improved patient outcomes.
  • The review highlights current and emerging treatment strategies for eosinophilic diseases.